Drug WatchTwo New Drugs Approved for Non–Small Cell Lung CancerAschenbrenner, Diane S. MS, RN Author Information Diane S. Aschenbrenner is a former member of the faculty at Notre Dame of Maryland University and the Johns Hopkins University School of Nursing. She coordinates Drug Watch: [email protected]. AJN, American Journal of Nursing 122(12):p 22-23, December 2022. | DOI: 10.1097/01.NAJ.0000904080.71037.14 Buy Metrics Abstract The Food and Drug Administration (FDA) has approved capmatinib (Tabrecta) for the treatment of metastatic non–small cell lung cancer in adults whose tumors have a mutation leading to mesenchymal-epithelial transition exon 14 skipping. Nurses should monitor patients for serious adverse effects such as interstitial lung disease/pneumonitis, hepatotoxicity, pancreatic toxicity, photosensitivity, and embryo–fetal toxicity. The FDA has granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu) for the treatment of unresectable or metastatic non–small cell lung cancer in adults whose tumors have activating human epidermal growth factor receptor 2 mutations and who have received a prior systemic therapy. Enhertu carries a boxed warning regarding the risk of interstitial lung disease and embryo–fetal toxicity. Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
